

PG3602USw

Remarks

Claims 1-10, 17-23, 26, 28, 29, and 35-40 are pending in the application before entry of this amendment. Claims 7 and 35 stand allowed. Claims 2-5, 10, 17, 26, and 28 stand as allowable but for being dependent upon rejected base claims. By way of this amendment, claims 1, 6, 8, 9, 18-23, 26, 29, and 36-40 have been amended, no claims have been canceled, and no claims have been newly added. No new matter has been added.

Rejections under 35 USC 112, First Paragraph

Claims 1, 6, 8, 9, and 18-23 stand rejected under 35 USC 112, first paragraph on the grounds that recitation of "solvate, ester or amide or salt or solvate of such ester or amide" is lacking enablement. The rejected language has been canceled herein. As such, Applicants submit that the rejection of claims 1, 6, 8, 9, and 18-23 has been overcome.

Claims 29 and 36-40 are rejected under 35 USC 112, first paragraph on the grounds that the claims should recite treatment of symptoms rather than etiology of the disease. As recommended by the Examiner, claims 29, and 36-40 have been amended to depend from claim 26. As such, Applicants submit that the rejection of claims 29 and 36-40 has been overcome.

Conclusion

The present Amendment is filed within the shortened two month period from the date of the action. Furthermore, Applicants assert that the instant Amendment places the application in a condition for allowance, or in the alternative, that its entry is appropriate as the instant amendments place the application in a better condition for appeal, as permitted by 37 CFR 1.116.

PG3602USw

The Examiner is invited to contact the undersigned at (919) 483-8160, to discuss this case, if desired.

Respectfully submitted,


J. Scott Young
Attorney for Applicants
Reg. No. 45,582

Date: Nov 28, 2006
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709
(919) 483-8160
fax: (919) 483-7988
Scott.S.Young@GSK.com